AbbVie Management
Management Kriterienprüfungen 2/4
Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Wichtige Informationen
Robert Michael
Geschäftsführender
US$32.5m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 5.23% |
| Amtszeit als Geschäftsführer | 2yrs |
| Eigentum des Geschäftsführers | 0.01% |
| Durchschnittliche Amtszeit des Managements | 2.3yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 8.7yrs |
Jüngste Management Updates
Recent updates
Narrative-Update • Jul 10
ABBV: Future Returns Will Depend On Apogee Deal And Broader Immunology Expansion
AbbVie’s refreshed analyst price target framework edges higher to about $259 from roughly $254, with analysts pointing to updated Q2 models, recent target hikes across several firms, and added confidence around the Apogee acquisition’s immunology and respiratory potential as key supports for the revision. Analyst Commentary Recent research on AbbVie centers on two main themes, the refreshed Q2 earnings models and the planned Apogee Therapeutics acquisition.Narrative-Update • Jun 23
ABBV: Future Returns Will Hinge On Apogee Deal And Immunology Pipeline
Analysts have made only a modest adjustment to AbbVie’s fair value narrative, reflecting a slightly higher discount rate and updated views on margins and long term P/E in light of the proposed $10.9 billion Apogee Therapeutics deal and its implications for competition and atopic dermatitis market potential. Analyst Commentary Recent research on AbbVie around the proposed US$10.9b Apogee Therapeutics acquisition highlights a mix of optimism about growth opportunities in immunology and atopic dermatitis, alongside caution about execution risk, competition, and valuation.Seeking Alpha • Jun 19
AbbVie: Immunology Cash Flow Funds Oncology Expansion
Summary I continue to cover AbbVie with a 'Buy' rating due to its R&D achievements. So, in the past 3 months, Decnupaz and Skinvive by Juvederm have received FDA approvals. Moreover, a week ago, AbbVie reported promising results from the Phase 3 CLL14 trial for the treatment of chronic lymphocytic leukemia patients. Meanwhile, Venclexta generated $770 million in revenue for AbbVie in Q1, up 15.8% year-over-year and 8.5% QoQ. Also, inthis article, you will know why the superiority of UCB's Bimzelx over Skyriziin the Phase 3 BE BOLD study doesn't threaten the sales growth of AbbVie's IL-23 inhibitor. Read the full article on Seeking AlphaAnalyseartikel • Jun 16
AbbVie (ABBV) Stock Could Be 12.6% Undervalued After CLL14 Trial Update
AbbVie (ABBV) is back in focus after releasing nine year final results from its Phase 3 CLL14 trial, where a fixed duration venetoclax plus obinutuzumab regimen improved progression free survival in untreated CLL patients. See our latest analysis for AbbVie. The latest CLL14 update lands after a mixed few sessions for AbbVie, with the share price slipping 2.7% on the day to $221.59, while still showing a 5.3% 30 day share price return and a 19.9% one year total shareholder return that points...Narrative-Update • Jun 06
ABBV: Future Returns Will Depend On Expanding Immunology And IBD Pipeline Execution
AbbVie’s updated analyst price target edges higher to $253.55 from $249.43 as analysts factor in slightly higher profit margin assumptions, modestly lower revenue growth expectations, a reduced discount rate, and a somewhat lower future P/E multiple, with recent research highlighting the depth of the inflammatory bowel disease pipeline and broader R&D optionality. Analyst Commentary Recent Street research on AbbVie shows a mix of optimism and caution, with multiple price target revisions clustered within a relatively tight range and commentary that keeps attention on the inflammatory bowel disease pipeline and broader R&D portfolio.Analyseartikel • May 15
We Think You Can Look Beyond AbbVie's (NYSE:ABBV) Lackluster Earnings
The market was pleased with the recent earnings report from AbbVie Inc. ( NYSE:ABBV ), despite the profit numbers being...Narrative-Update • Apr 23
ABBV: Future Returns Will Rely On Immunology Expansion And Operating Leverage Execution
Analysts made a small upward adjustment to AbbVie’s fair value estimate to about $249. The modest change reflects a mix of slightly higher assumed discount rates and future P/E multiples, alongside recent shifts in Street price targets, including both raises and trims from firms such as Piper Sandler, Guggenheim, Cantor Fitzgerald, Evercore ISI, Citi and UBS, as well as fresh bullish initiations from Canaccord, RBC Capital and Barclays.Narrative-Update • Apr 08
ABBV: Future Returns Will Hinge On Immunology Encore And Operating Leverage Execution
Analysts have made a modest upward adjustment to AbbVie’s price target, reflecting updated views on its immunology pipeline potential, operating leverage, and the ongoing debate about whether recent share underperformance and selloffs adequately reflect competitive risks. Analyst Commentary Recent research on AbbVie highlights a split view, with some analysts focusing on the upside from the immunology pipeline and operating leverage, while others point to valuation and competitive questions after a period of share underperformance.Narrative-Update • Mar 24
ABBV: Future Returns Will Hinge On Immunology Encore Outweighing Competitive Concerns
Narrative Update The analyst price target for AbbVie has been adjusted slightly higher to reflect a fair value move to about $249. Analysts point to early stage indication expansion, operating leverage potential, and ongoing immunology pipeline developments, even as some firms flag emerging competition and a more balanced risk and reward profile.Narrative-Update • Mar 10
ABBV: Future Returns Will Depend On Immunology Encore And Deal Optionality Uncertainty
The analyst price target for AbbVie edges higher to align with our fair value shift from $248.29 to $248.86, as analysts highlight ongoing indication expansion in immunology, potential operating leverage, and multiple expansion drivers, even as some firms note emerging competition and a more balanced risk and reward profile. Analyst Commentary Recent research on AbbVie reflects a split view, with some analysts pointing to upside tied to immunology growth and pipeline execution, while others flag competition risk and a more balanced risk and reward profile at current levels.Narrative-Update • Feb 22
ABBV: Future Returns Will Rely On Immunology Encore And Evolving Deal Optionality
Our updated AbbVie narrative reflects a modest price target increase to about $248 per share, as analysts point to potential operating leverage, room for P/E multiple expansion, and a pipeline of proof-of-concept and immunology programs that could support slightly higher revenue growth assumptions, even as margin expectations are trimmed. Analyst Commentary Recent research shows a mix of optimism and caution around AbbVie, with several firms adjusting price targets and ratings as they reassess execution risks, competitive pressures, and the potential impact of the pipeline on valuation.Narrative-Update • Feb 07
ABBV: Future Returns Will Depend On Immunology Pipeline Clarity And M&A Uncertainty
Analysts have trimmed their price targets for AbbVie by a small amount. This reflects slightly lower revenue growth and P/E assumptions, while also incorporating a modestly higher profit margin and recent mixed research views around competition and pipeline visibility.Narrative-Update • Jan 24
ABBV: Future Returns Will Hinge On Post-Humira Immunology And Deal Optionality
Analysts have nudged their price target for AbbVie slightly higher to reflect a fair value estimate of about $245 per share, supported by updated assumptions for revenue growth, profit margins, and a modestly lower future P/E. Recent research highlights both increased price targets and more cautious views around competition and the sustainability of outperformance in key immunology drugs.Narrative-Update • Jan 09
ABBV: Future Returns Will Depend On Post-Humira Immunology And Pipeline Execution
Analysts have trimmed their AbbVie fair value estimate by about $0.10 per share to roughly $244.56. This reflects a mix of slightly higher risk assumptions, modestly adjusted revenue and margin expectations, and a more balanced set of views after recent downgrades and price target changes that suggest outperformance is already well reflected in the current share price.Analyseartikel • Jan 08
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 17th of February to...Narrative-Update • Dec 21
ABBV: Future Returns Will Hinge On Post-Humira Immunology And Pipeline Execution
Analysts have nudged our AbbVie fair value estimate slightly higher, from $243.55 to $244.68. This reflects modestly stronger long term revenue growth expectations for key immunology franchises and pipeline assets, partially offset by slightly lower margin assumptions and a broadly constructive but mixed backdrop of recent price target revisions and rating changes across the Street.Narrative-Update • Dec 07
ABBV: Future Performance Will Depend On Extended Exclusivity And Pipeline Execution
Analysts have nudged their average price target on AbbVie modestly higher to reflect a wave of target increases into the mid 240s to low 260s dollar range, supported by stronger visibility into Skyrizi and Rinvoq driven growth, extended Rinvoq exclusivity, and a more favorable large cap biopharma backdrop despite mixed ratings changes. Analyst Commentary Recent research paints a generally constructive picture on AbbVie, with most price target revisions skewing higher even as some firms move to the sidelines.Analyseartikel • Dec 02
AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73
The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...Narrative-Update • Nov 23
ABBV: Future Performance Will Depend On Pipeline Expansion And Patent Protections
AbbVie’s analyst price target has increased modestly from $241.29 to $243.55. Analysts cite resilient performance in immunology products, extended Rinvoq exclusivity, and improving fundamentals as key drivers of sentiment.Analyseartikel • Nov 18
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...Narrative-Update • Nov 08
ABBV: Future Performance Will Reflect Balance Between Patent Wins and Product Pressures
AbbVie's analyst price target has risen modestly from $237.48 to $241.29. Analysts cite resilient fundamentals and long-term patent settlements, which help offset recent industry downgrades and softer performance in some business units.Narrative-Update • Oct 25
Continued Expansion in Neuroscience and Immunology Will Drive Leadership Beyond 2025
AbbVie's analyst price target has been raised from approximately $233 to $237 per share. Analysts cite ongoing revenue growth, improved margins, and extended exclusivity for key products as the main drivers behind the upward revision.Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$4b |
| Dec 31 2025 | US$33m | US$2m | US$4b |
| Sep 30 2025 | n/a | n/a | US$2b |
| Jun 30 2025 | n/a | n/a | US$4b |
| Mar 31 2025 | n/a | n/a | US$4b |
| Dec 31 2024 | US$18m | US$2m | US$4b |
| Sep 30 2024 | n/a | n/a | US$5b |
| Jun 30 2024 | n/a | n/a | US$5b |
| Mar 31 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$14m | US$1m | US$5b |
| Sep 30 2023 | n/a | n/a | US$6b |
| Jun 30 2023 | n/a | n/a | US$9b |
| Mar 31 2023 | n/a | n/a | US$8b |
| Dec 31 2022 | US$10m | US$1m | US$12b |
| Sep 30 2022 | n/a | n/a | US$13b |
| Jun 30 2022 | n/a | n/a | US$13b |
| Mar 31 2022 | n/a | n/a | US$12b |
| Dec 31 2021 | US$12m | US$1m | US$11b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$7b |
| Mar 31 2021 | n/a | n/a | US$5b |
| Dec 31 2020 | US$13m | US$1m | US$5b |
| Sep 30 2020 | n/a | n/a | US$7b |
| Jun 30 2020 | n/a | n/a | US$7b |
| Mar 31 2020 | n/a | n/a | US$8b |
| Dec 31 2019 | US$9m | US$907k | US$8b |
Vergütung im Vergleich zum Markt: RobertDie Gesamtvergütung ($USD32.53M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD14.60M).
Entschädigung vs. Einkommen: RobertDie Bezüge der Mitarbeiter sind um mehr als 20 % gestiegen, während die Unternehmensgewinne im vergangenen Jahr um mehr als 20 % gesunken sind.
Geschäftsführer
Robert Michael (56 yo)
2yrs
Amtszeit
US$32,530,984
Vergütung
Mr. Robert A. Michael, C.P.A., served as Chief Operating Officer at AbbVie Inc. since June 29, 2023 until July 01, 2024 and served as its President since June 23, 2022 until July 01, 2024 also serves as it...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO & Chairman of the Board | 2yrs | US$32.53m | 0.010% $ 44.4m | |
| Executive VP & CFO | 4.1yrs | US$12.35m | 0.0022% $ 9.6m | |
| Executive VP & COO | 2yrs | US$10.79m | 0.012% $ 50.7m | |
| Executive VP of Research & Development and Chief Scientific Officer | 2yrs | US$9.91m | 0.0031% $ 13.7m | |
| Executive VP & Chief Commercial Officer | no data | US$15.44m | 0.0048% $ 21.0m | |
| Senior VP & Chief Information Officer | less than a year | keine Daten | keine Daten | |
| Senior Vice President of Investor Relations | no data | keine Daten | keine Daten | |
| Executive VP | 3.8yrs | keine Daten | 0.00026% $ 1.1m | |
| Executive VP & Chief Human Resources Officer | 1.5yrs | keine Daten | 0.00045% $ 2.0m | |
| Senior VP & President of Oncology | 2.8yrs | keine Daten | keine Daten | |
| Executive VP and Chief Business & Strategy Officer | 3.5yrs | keine Daten | 0.0042% $ 18.5m | |
| Senior Vice President of Corporate Affairs | 2.5yrs | keine Daten | keine Daten |
2.3yrs
Durchschnittliche Betriebszugehörigkeit
55yo
Durchschnittliches Alter
Erfahrenes Management: ABBVDas Führungsteam des Unternehmens gilt als erfahren (2.3 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO & Chairman of the Board | 2yrs | US$32.53m | 0.010% $ 44.4m | |
| Lead Independent Director | 13.5yrs | US$432.88k | 0.00065% $ 2.8m | |
| Independent Director | 6.2yrs | US$397.88k | 0.0071% $ 31.1m | |
| Independent Director | 1.2yrs | US$328.71k | 0.00017% $ 745.1k | |
| Independent Director | 13.5yrs | US$383.44k | 0.0010% $ 4.4m | |
| Independent Director | 13.5yrs | US$382.88k | keine Daten | |
| Independent Director | 13.5yrs | US$402.88k | 0.00011% $ 482.1k | |
| Independent Director | 9.2yrs | US$407.88k | 0% $ 0 | |
| Independent Director | 10.5yrs | US$397.88k | keine Daten | |
| Independent Director | 8.2yrs | US$372.88k | keine Daten | |
| Independent Director | 2.8yrs | US$359.51k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$372.88k | 0% $ 0 |
8.7yrs
Durchschnittliche Betriebszugehörigkeit
67.5yo
Durchschnittliches Alter
Erfahrener Vorstand: ABBVDie Vorstandsmitglieder gelten als erfahren (8.7 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/13 12:11 |
| Aktienkurs zum Tagesende | 2026/07/10 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
AbbVie Inc. wird von 51 Analysten beobachtet. 24 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Luisa Hector | Berenberg |